Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06918561 · ClinicalTrials.gov registry record · NA
Evaluating the Efficacy of NeoThelium FT in the Treatment of Chronic Open Wounds
A NA study of Open Wound, sponsored by NuScience Medical Biologics.
- Recruiting
- Registry status
- NA
- Development phase
- 132
- Enrollment target
- 3
- Study locations
NCT06918561 is a NA study of Open Wound that is actively recruiting participants, run by NuScience Medical Biologics. The registered enrollment target is 132 participants, above the 22-participant average among 3 other Open Wound trials with a reported enrollment target (500% higher). The trial reports 3 study locations across 2 states.
The verdict
NCT06918561, a NA study of Open Wound, is actively recruiting participants, sponsored by NuScience Medical Biologics.
- RECRUITING
- Registry status
- NA
- Development phase
- 132 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
Conditions Studied
Interventions
- OTHER Standard of Care
- OTHER NeoThelium FT
Study Locations (3)
Louisiana
- MedCentris of Hammond - Hammond
- MedCentris of Slidell - Slidell
Mississippi
- MedCentris of D'iberville - D'Iberville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2026-10-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06918561
The ClinicalTrials.gov registry entry for NCT06918561 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 22-participant average among 3 other Open Wound trials with a reported enrollment target (500% higher). The listed sponsor is NuScience Medical Biologics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Open Wound appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT06918561 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Louisiana, Mississippi.
Frequently Asked Questions
What is clinical trial NCT06918561 about?
NCT06918561 is a clinical study titled "Evaluating the Efficacy of NeoThelium FT in the Treatment of Chronic Open Wounds". This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
What is the current status of trial NCT06918561?
This trial is currently recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2025-10-16. Estimated completion is 2026-10-01.
What conditions does trial NCT06918561 study?
This clinical trial studies the following conditions: Open Wound.
What interventions are being tested in trial NCT06918561?
The interventions under investigation include: Standard of Care (OTHER), NeoThelium FT (OTHER).
Who is sponsoring clinical trial NCT06918561?
This trial is sponsored by NuScience Medical Biologics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06918561 being conducted?
This trial has 3 study locations across Louisiana, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Wound
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.